Proton-Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Population-Based Study.
Proton-Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Population-Based Study.
复制标题
DOI：
10.1002/acr.24876
复制
发表时间：
2022-12
影响因子：
4.7
通讯作者：
Neogi, Tuhina
中科院分区：
文献类型：
--
作者：
Liew, Jean W.;Peloquin, Christine;Tedeschi, Sara K.;Felson, David T.;Zhang, Yuqing;Choi, Hyon K.;Terkeltaub, Robert;Neogi, Tuhina
There are no proven effective medical treatments to prevent calcium pyrophosphate crystal deposition (CPPD). Hypomagnesemia is a known CPPD risk factor. We carried out a real-world epidemiologic study on proton pump inhibitor (PPI) use, which can cause hypomagnesemia, and CPPD risk. We conducted a time-stratified, propensity score (PS)-matched cohort study using the UK-based IQVIA Medical Research Data. We compared risk of incident CPPD among PPI users versus H2 blocker users using Cox proportional hazard models. We used greedy matching of incident PPI users 1:1 to incident histamine receptor 2 (H2) blocker users in 1-year cohort accrual blocks. Subjects were censored at time of drug switch. We evaluated incident use of PPI and H2 blockers prior to incident CPPD using a nested case-control study within the same cohort, matched 1:4 by age and sex using risk-set sampling. We identified 81,102 PPI and H2 blocker initiators, with 113 and 63 incident cases of CPPD, respectively. In the case-control study when compared with non-users, both PPI and H2B users had higher risk of incident CPPD (OR 1.79, 1.79 [95% CI 1.55, 2.07] and OR 1.52 [95% CI 1.14, 2.03], respectively). Incident PPI use was nonsignificantly associated with incident CPPD, HR 1.03 (95% CI 0.75, 1.41) compared with H2 blocker use. In this study using real-world data, incident use of PPIs was not associated with a higher risk of CPPD compared with incident H2 blocker use, although use of PPI and H2 blockers had higher risk compared to non-use.
登录
查看更多内容
影响因子：
4.7
作者：
Kleiber Balderrama, Crystal;Rosenthal, Ann K.;Bartels, Christie M.
通讯作者：
Bartels, Christie M.
质子泵抑制剂在美国门诊环境中的使用，2002-2009 年。
影响因子：
3.7
作者：
Rotman SR;Bishop TF
通讯作者：
Bishop TF
影响因子：
13.2
作者：
Kieboom, Brenda C. T.;Kiefte-de Jong, Jessica C.;Hoorn, Ewout J.
通讯作者：
Hoorn, Ewout J.
影响因子：
2.6
作者：
Seeger, JD;Williams, PL;Walker, AM
通讯作者：
Walker, AM
影响因子：
5
作者：
Brookhart, M. Alan;Schneeweiss, Sebastian;Sturmer, Til
通讯作者：
Sturmer, Til